Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients

Pauline L. de Goeje, Myrthe Poncin, Koen Bezemer, Margaretha E. H. Kaijen-Lambers, Harry J. M. Groen, Egbert F. Smit, Anne-Marie C. Dingemans, Andre Kunert, Rudi W. Hendriks, Joachim G. J. V. Aerts*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2219-2227
Number of pages9
JournalClinical Cancer Research
Volume25
Issue number7
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • PEMBROLIZUMAB
  • CHEMOTHERAPY
  • IMMUNITY
  • STAGE
  • BLOOD

Cite this

de Goeje, P. L., Poncin, M., Bezemer, K., Kaijen-Lambers, M. E. H., Groen, H. J. M., Smit, E. F., Dingemans, A-M. C., Kunert, A., Hendriks, R. W., & Aerts, J. G. J. V. (2019). Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. Clinical Cancer Research, 25(7), 2219-2227. https://doi.org/10.1158/1078-0432.CCR-18-2243